Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Forest’s Antipsychotic Cariprazine Clears Last Clinical Hurdle To Double NDA Filing In 2012

Feb 28 2012

• By Shirley Haley

Related Content

Teva’s U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy <em>Lipitor</em> Deal

Feb 16 2012

Lots Of Activity In Forest Pipeline, But Can The Specialty Pharma Ever Put <i>Lexapro</i> Behind It?

Apr 25 2011

MDD Market Snapshot: Depressing Future For Antidepressants

Aug 15 2011

Forest Ready To File Antipsychotic Cariprazine With Bipolar Mania Results

Oct 05 2011

Related Companies

Forest Laboratories, Inc.

Bristol Myers Squibb Company

Otsuka Holdings Co., Ltd.

Gedeon Richter Plc.

Teva Pharmaceutical Industries Ltd.

Viatris Inc.

Additional Topics

Research & Development BioPharmaceutical

More from R&D

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window